Answers are grounded in this paper and cite their sources.
BACKGROUND: Real-world comparative outcomes of regorafenib versus immune checkpoint inhibitors (ICI) after chemotherapy in colorectal cancer (CRC) are limited. METHODS: Using de-identified multicenter University of California Health EHR data (2012-2025), we identified chemotherapy-exposed CRC patients initiating regorafenib (C/R, n = 653) or ICI (C/I, n = 382) with mutually exclusive exposure groups. Time-to-event analyses were anchored at therapy initiation (index date). Overall survival was compared using Kaplan-Meier and multivariable Cox models. To enhance interpretability and bias control, we also estimated 3- and 5-year restricted mean survival time (RMST) differences and conducted a propensity-score overlap-weighted Cox sensitivity analysis with balance diagnostics. Post-treatment carcinoembryonic antigen (CEA) levels were compared using Wilcoxon testing. RESULTS: Survival differed between groups (log-rank p = 0.0195). Five-year Kaplan-Meier survival was 33.2% (95% CI 29.8-37.0) for C/R and 41.5% (36.7-46.9) for C/I (absolute difference 8.2 percentage points). In adjusted Cox models, C/R was associated with higher mortality risk than C/I (HR 1.217, 95% CI 1.021-1.450; p = 0.0282). RMST favored C/I at 3 years (difference 95.6 days, 95% CI 39.4-148.6) and 5 years (168.0 days, 95% CI 69.1-262.8). Overlap-weighted estimates were consistent (HR for C/I vs C/R 0.802, 95% CI 0.672-0.958; p = 0.0151). Post-treatment CEA was higher in C/R (Hodges-Lehmann difference 8.70; p < 0.0001). CONCLUSION: In this real-world cohort, initiating immunotherapy was associated with improved survival versus regorafenib after chemotherapy, and post-treatment CEA differed between groups, supporting its potential prognostic value.
No takes yet. Share an insight, caveat, or question.
Farzana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: